MECHANISMS OF CELL POLARITY ESTABLISHMENT
细胞极性建立机制
基本信息
- 批准号:7932406
- 负责人:
- 金额:$ 6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-30 至 2010-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAntigen PresentationApicalBehaviorBindingBrainCDC42 geneCNTNAP1 geneCell PolarityCell divisionCell physiologyCell-Cell AdhesionCellsCellular MorphologyCellular StructuresCystDataDendritic SpinesEnvironmentEpithelial CellsEscherichia coliEventExhibitsFaceFundingGTP-Binding ProteinsGenerationsGerm CellsGrantGuanosine Triphosphate PhosphohydrolasesHippocampus (Brain)HumanLifeLinkMDCK cellMalignant NeoplasmsMemoryModelingMolecularMonomeric GTP-Binding ProteinsMorphogenesisNeuronsOrganismPARD6A genePathway interactionsProcessPropertyProteinsRNA InterferenceRoleSaccharomycetalesSignal PathwaySignal TransductionStem cellsSurfaceSynapsesSystemTIAM1 geneTestingWorkaxon guidancebasecell motilitycell typecellular imaginghuman JTB proteininsightinterestnovelpublic health relevancerhorho GTP-Binding Proteinsrho GTPase-activating proteintumor progression
项目摘要
DESCRIPTION (provided by applicant): Cell polarization is one of the most fundamental organizational aspects of life, from single-celled organisms such as E. coli and budding yeast up to the wiring of the human brain. Cell polarization is required for the generation of diverse cell types from stem cells, for morphogenesis, directional motility, antigen presentation, and axon guidance; and the loss of cell polarity is a critical step in cancer progression. The wide interest in cell polarity has pushed rapid progress in understanding the scope and complexity of the polarization machinery. However, the fundamental question of how the polarity proteins operate to organize cell structure remains largely unanswered. This proposal builds on progress over the last funding period to address these questions. Our objective is to understand the connections between the PAR polarity proteins and small GTPases. We will focus on MDCK epithelial cell polarization in 3D cultures, and on dendritic spine morphogenesis in hippocampal neurons - two tractable systems in which the PAR proteins have defined but distinct roles. The specific aims are as follows: 1. Identify the molecular mechanisms through which PAR-3, PAR-6, and aPKC organize the apical domain (which we term a "patch") during polarized cyst formation of MDCK cells. Using live cell imaging, we will investigate the earliest steps in polarization, which occur during the initial cell division of cells grown in 3D cultures. We will test a new model in which cytokinetic events are proposed to generate the landmark for apical patch assembly. 2. Determine the role of CDC42 in assembly of the apical patch, and identify the CDC42 GEF and GAP that are necessary for cell polarization. RNAi screens are being used to identify the GEF and GAP. Based on preliminary data from a GEF RNAi screen, we propose that a CDC42-GEF called Tuba drives recruitment of PAR-6/aPKC and apicalization. 3. Identify the mechanisms by which PAR-3 controls TIAM1 function in neurons; and determine how PAR- 6, independently of PAR-3, regulates dendritic spine morphogenesis via the Rho GTPase. We will determine the molecular basis for activation of p190 RhoGAP by PAR-6/aPKC. The mechanism by which PAR-6 regulates synaptic activity in hippocampal neurons will also be investigated. Together, these studies will provide new insights into the fundamentally important process of cell polarization, and into the ways by which the PAR polarity proteins exhibit context-specific behavior to control different aspects of cell morphology. PUBLIC HEALTH RELEVANCE: Over 90% of all human cancers originate from epithelial cells. A key property of epithelial cells is that they adhere to one another to form sheets in which the upper surface (which faces the environment) is functionally different from the bottom surface. Cancer progression involves the temporary loss of this cell-cell adhesion, and of up-down polarity. Thus, to understand human cancer, and to identify new chemotherapeutic targets, it is important to find out how epithelial cells polarize. Remarkably, the same process that helps these cells stick to one another is also essential for making the contacts between nerve cells in the brain, which enable us to think and store memories. This grant investigates the detailed molecular mechanisms that enable epithelial cells and nerve cells to polarize and form junctions, and will provide new insights into these mechanisms.
描述(由申请人提供):细胞极化是生命最基本的组织方面之一,从单细胞生物如E。大肠杆菌和芽殖酵母直到人类大脑的布线。细胞极化是从干细胞产生不同细胞类型所必需的,用于形态发生、定向运动、抗原呈递和轴突引导;细胞极性的丧失是癌症进展中的关键步骤。对细胞极性的广泛兴趣推动了对极化机制的范围和复杂性的理解的快速进展。然而,极性蛋白如何组织细胞结构的基本问题在很大程度上仍然没有答案。本提案是在上一个供资期间为解决这些问题而取得的进展的基础上提出的。我们的目标是了解PAR极性蛋白和小GTP酶之间的联系。我们将专注于MDCK上皮细胞极化的三维文化,并在海马神经元树突棘形态发生-两个易于处理的系统中,PAR蛋白的定义,但不同的角色。具体目标如下:1.鉴定PAR-3、PAR-6和aPKC在MDCK细胞极化囊肿形成过程中组织顶端结构域(我们称之为“斑块”)的分子机制。使用活细胞成像,我们将研究极化的最早步骤,这发生在3D培养物中生长的细胞的初始细胞分裂期间。我们将测试一个新的模型,其中提出了细胞动力学事件,以产生顶端补丁组装的标志。2.确定CDC 42在根尖片组装中的作用,并鉴定细胞极化所必需的CDC 42 GEF和GAP。RNAi筛选被用于鉴定GEF和GAP。基于来自GEF RNAi筛选的初步数据,我们提出称为Tuba的CDC 42-GEF驱动PAR-6/aPKC的募集和顶端化。3.确定PAR-3控制神经元中TIAM 1功能的机制;并确定PAR- 6如何独立于PAR-3通过Rho GT3调节树突棘形态发生。我们将确定PAR-6/aPKC激活p190 RhoGAP的分子基础。PAR-6调节海马神经元突触活动的机制也将被研究。总之,这些研究将提供新的见解细胞极化的根本重要的过程,并进入PAR极性蛋白表现出特定的行为,以控制细胞形态的不同方面的方式。公共卫生相关性:超过90%的人类癌症起源于上皮细胞。上皮细胞的一个关键特性是它们彼此粘附以形成薄片,其中上表面(其面向环境)在功能上不同于底表面。癌症进展涉及这种细胞-细胞粘附和上下极性的暂时丧失。因此,为了了解人类癌症,并确定新的化疗靶点,重要的是要找出上皮细胞是如何增殖的。值得注意的是,帮助这些细胞相互粘附的过程对于大脑中神经细胞之间的联系也是必不可少的,这使我们能够思考和存储记忆。这项资助研究了使上皮细胞和神经细胞能够生长并形成连接的详细分子机制,并将为这些机制提供新的见解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
IAN G MACARA其他文献
IAN G MACARA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('IAN G MACARA', 18)}}的其他基金
相似海外基金
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
- 批准号:
10836880 - 财政年份:2023
- 资助金额:
$ 6万 - 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
- 批准号:
10734324 - 财政年份:2023
- 资助金额:
$ 6万 - 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
- 批准号:
10740465 - 财政年份:2023
- 资助金额:
$ 6万 - 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
- 批准号:
23K04971 - 财政年份:2023
- 资助金额:
$ 6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
- 批准号:
2885451 - 财政年份:2023
- 资助金额:
$ 6万 - 项目类别:
Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
- 批准号:
10385926 - 财政年份:2022
- 资助金额:
$ 6万 - 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
- 批准号:
10509043 - 财政年份:2022
- 资助金额:
$ 6万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10704008 - 财政年份:2022
- 资助金额:
$ 6万 - 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
- 批准号:
10818273 - 财政年份:2022
- 资助金额:
$ 6万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10349397 - 财政年份:2022
- 资助金额:
$ 6万 - 项目类别: